Additional Information
Market: TSX-V
Sector: Pharmaceuticals
EPIC: DMA
Latest Price: 0.62  (0,00%)
52-week High: 1.49
52-week Low: 0.58
Market Cap: 38.46M
1 year chart
1 day chart
DiaMedica Inc. (DiaMedica) is a biopharmaceutical company that develops therapeutic products designed for Type 1 diabetes, Type 2 diabetes treatment and certain other medically-unmet diseases.

DiaMedica says diabetic drug shows positive results in preclinical study

16th Oct 2012, 3:30 pm by Brad Lemaire
'The results from this study suggest DM-199 co-administered with basal long-acting insulin may reduce the need for short-acting insulin around meals while improving glucose control in diabetic patients,' chief executive Rick Pauls said in a statement. "The results from this study suggest DM-199 co-administered with basal long-acting insulin may reduce the need for short-acting insulin around meals while improving glucose control in diabetic patients," chief executive Rick Pauls said in a statement.

DiaMedica (CVE:DMA) said Tuesday its experimental drug DM-99 for Type 1 and 2 diabetes confirmed it lowers daily insulin needs when taken with long-acting, basal insulin like Lantus.

The Winnipeg-based company said full results from the preclinical study will be published, but did not provide a date.

DiaMedica said the study revealed DM-99 alone lowers fasting glucose values in a diabetic model. 

During a tolerance test, the drug, when taken with long-acting insulin, significantly cut sugar levels immediately and well after a meal to near normal levels. 

"The results from this study suggest DM-199 co-administered with basal long-acting insulin may reduce the need for short-acting insulin around meals while improving glucose control in diabetic patients," chief executive Rick Pauls said in a statement.

"Lowering the frequency and amount of daily insulin injections and reducing the risk of hypoglycemia could significantly improve the quality of life for Type 1 diabetics and possibly for Type 2 diabetics. 

"Results are to be confirmed in future human studies."

DiaMedica is a biopharmaceutical firm focused on discovering and developing new therapies to treat diabetes and complications tied to the disease. 

The company is also developing, DM-204, a drug used to treat Type 2 diabetes. In a pre-clinical trial, the drug revealed major improvement in blood sugar control, blood pressure and cholesterol levels, it said. 

Shares in the company were trading at $1.80 on the TSX Venture Exchange. Its stock spiked to $1.94 in early morning trading.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here